Rapid Therapeutic Science Laboratories, Inc. (RTSL) Accumulated Depreciation & Amortization (2020 - 2023)
Rapid Therapeutic Science Laboratories' Accumulated Depreciation & Amortization history spans 4 years, with the latest figure at $65313.0 for Q2 2023.
- For Q2 2023, Accumulated Depreciation & Amortization rose 57.99% year-over-year to $65313.0; the TTM value through Jun 2023 reached $65313.0, up 57.99%, while the annual FY2022 figure was $53327.0, 81.66% up from the prior year.
- Accumulated Depreciation & Amortization for Q2 2023 was $65313.0 at Rapid Therapeutic Science Laboratories, up from $59320.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $65313.0 in Q2 2023 and bottomed at $2418.0 in Q3 2020.
- The 4-year median for Accumulated Depreciation & Amortization is $32351.5 (2021), against an average of $32993.8.
- The largest annual shift saw Accumulated Depreciation & Amortization skyrocketed 885.53% in 2021 before it soared 57.99% in 2023.
- A 4-year view of Accumulated Depreciation & Amortization shows it stood at $7255.0 in 2020, then skyrocketed by 304.62% to $29355.0 in 2021, then skyrocketed by 81.66% to $53327.0 in 2022, then increased by 22.48% to $65313.0 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Accumulated Depreciation & Amortization are $65313.0 (Q2 2023), $59320.0 (Q1 2023), and $53327.0 (Q4 2022).